Monday, November 20, 2017

Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers

Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said.

from Forbes Real Time https://www.forbes.com/sites/matthewherper/2017/11/20/roche-cancer-drug-rises-to-challenge-merck-bristol-myers/
via IFTTT

No comments:

Post a Comment